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Background: Obesity is a growing health problem leading to high rates of mortality and morbidity in patients with
severe mental illness (SMI). The increased rate of obesity is largely attributed to antipsychotic use. The effect of
antipsychotic medications on H1 and 5HT2 receptors has been associated with weight gain, but there is also a
substantial amount of evidence showing that D2 receptor blockade may be responsible for weight gain by
interacting with the dopamine-opioid system. Unfortunately, current available medications for weight loss have
limited efficacy in this population. Naltrexone, an opioid receptor antagonist, may be a promising agent to reduce
antipsychotic induced weight gain by decreasing food cravings. We aim to investigate the safety and efficacy of
two doses of naltrexone (25 mg & 50 mg) versus placebo for weight and health risk reduction in overweight and
obese individuals (BMI ≥ 28) with SMI, who gained weight while being treated with antipsychotics.
Methods and design: One hundred and forty four patients will be recruited throughout the greater New Haven
area. The participants will be randomized to naltrexone 25 mg/day, naltrexone 50 mg/day, or placebo in a 1:1:1
ratio. Participants will be on the study medication for 52 weeks, and assessed weekly for the first 4 weeks and
bi-weekly thereafter. The primary outcome measurements are weight reduction and percentage achieving clinically
significant weight loss (5% of total body weight). Waist circumference, body mass index, serum lipid profile, fasting
glucose, and glycosylated hemoglobin are the secondary outcome measures. The effect of naltrexone on other
outcome measurements such as schizophrenia symptoms, depression, dietary consumption, quality of life, cognitive
functioning, physical activity, metabolism/inflammation markers, serum leptin, ghrelin, peptide YY, adinopectin, high
sensitivity CRP, interleukin 6, interleukin-1B, interleukin-18, and tumor necrosis factor alpha (TNF-α) will be evaluated.
The data will be analyzed by applying linear mixed effect models.
Discussion: This is the first large scale study investigating the safety and efficacy of naltrexone in antipsychotic
induced weight gain; and hopefully, this may lead to a novel pharmacological option for management of this
major health problem.
Trial registration: This trial is registered in www.clinicaltrials.gov as NCT01866098
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Obesity is a growing health problem leading to high
rates of mortality and morbidity in patients with severe
mental illness (SMI) [1-4]. Studies demonstrate the
prevalence of obesity and related diseases are much
higher in patients with SMI than in general population
[2,5-7]. It was found that 42% of individuals with schizo-
phrenia had a Body Mass Index (BMI) of 27 or greater,
compared to 27% of the general population [8]. In the
Northern Finland 1966 birth cohort study, rates of obes-
ity in patients with schizophrenia were 42% compared to
13% for rest of the cohort [9]. A review of 45 studies in-
cluding patients with bipolar disorder shows the overall
prevalence of overweight and obesity is higher in bipolar
patients than in control populations [6]. The increased
rates of obesity can be mostly attributed to antipsychotic
(AP) medication use. In a landmark study, Allison et al.
reviewed available research data and found that, on aver-
age, patients gain weight after 10 weeks of treatment
with any antipsychotic medication, but that there were
differences across medications: patients taking clozapine
had a mean weight gain of 3.99 kg, followed by a mean
weight gain of 3.51 kg for olanzapine treated patients,
2.10 kg for chlorpromazine, 2.00 kg for risperidone, 0.48
kg for haloperidol, 0.43 kg for fluphenazine, and 0.04 kg
for ziprasidone [10]. In the CATIE trial, >7% of baseline
weight gain occurred in 30% of patients taking
olanzapine over 18 months, but only 7% to 16% of pa-
tients taking other antipsychotics had this clinically
significant weight gain [11]. Even aripiprazole and
ziprasidone, with their more favorable weight gain pro-
files, produce over 7% total body weight gain in approxi-
mately 10% of clinical trial subjects. In a large study of
first episode psychosis patients, participants gained an
average of 16 kg on olanzapine and 7.5 kg on haloperi-
dol [12]. The mechanism of weight gain associated
with the novel antipsychotics has not been fully eluci-
dated, but may be related to blockade of histamine
(H1), serotonin 2C (5HT2c) and alpha 1- adrenergic
receptors on hypothalamic neurons, resulting in distor-
tion of signals from the gastrointestinal (GI) tract to
the brain. [13-16]. While these two receptors may
explain the excess weight gain that is observed with
newer agents, they fail to explain the weight gain pro-
duced by agents like haloperidol, which have no affin-
ity to these receptors. In fact, the sole effect of
haloperidol is to block Dopamine 2 (D2) receptors, an
action that is shared to a varying degree by all ap-
proved antipsychotic agents. Thus, D2 receptor block-
ade appears to play an additional role in weight gain.
D2 receptors are not directly involved with energy
regulation; however, they do play an important role in
the brain's food reward system. Food is one of the pri-
mary substrates of the reward system in higher livingorganisms. Highly storable energy sources, such as fats
and sugars, are extremely enjoyable through the ac-
tions of opiate receptors, which are partly mediated by
D2 receptors [17]. D2 receptor blockade in animals is
shown to produce an effect similar to dilution of the
reward itself [18]. Blockade of D2 receptors may make
the whole system less sensitive to stimuli, and thereby
push the organism to eat more in order to achieve
similar levels of enjoyment.Reward system, opioid receptors and appetite
Like any non-automatic function that is essential for sur-
vival, mammalian feeding behavior is closely modulated
by the reward circuits in the brain. Endogenous opioids
play an important role in these reward circuits [19]. Fol-
lowing the discovery of endogenous opioids, it was
found that opioid receptor antagonists (ORA) decrease
self-feeding in food deprived rats [20]. Since then, the
animal literature has expanded significantly, and this
finding has been replicated in non-food deprived rats
and many other mammalian species [20]. It is now fairly
clear that ORAs have little effect on initiation of feeding,
but rather attenuates preference for “palatable diets” and
eating behavior [21]. Injecting animals with opioids in-
creases the preference for high carbohydrate, and even
more so, high fat diets, an effect readily blocked by
ORAs. There is no evidence that ORAs actually block
the taste sensation in animals or humans [20]. Human
studies revealed intact taste, but a decrease in the pleas-
antness of sweets, after administering the ORA naltrex-
one [19]. Since ORAs block the preference for saccharin
solutions in rats, it appears that the macronutrient or
caloric content of food does not activate opioid pathways
[22]. Other findings show that palatable foods result in
endogenous opiate release, related mRNA expression,
and opioid receptor occupation in sites of the brain that
are critical for both feeding and overall reward circuits,
most strikingly in the nucleus accumbens and hypo-
thalamus [19]. The rewarding effects of opioids are
exerted mainly through dopamine [17]. Obese human
subjects are shown to have significant increases in their
circulating β-endorphin levels compared to non-obese
controls [23]. Also, more palatable foods are shown to
induce higher circulating β-endorphin levels in normal
weight human subjects [24]. Increased extracellular
dopamine levels occur in the nucleus accumbens and
striatum in response to rewarding food stimuli. Not-
ably, obese subjects have been shown to have lower
striatal D2 receptor availability at a rate that is inversely
proportional to the level of obesity [25-27]. A mechan-
ism for obesity in this population has been proposed
here, in which overeating occurs as an attempt to
stimulate the dopamine system.
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gain
Patients with schizophrenia treated using antipsychotic
medications have been shown to have a preference for
diets high in fat and sugar [28]. Patients with schizo-
phrenia also typically seek behaviors that increase dopa-
mine mediated reward in the brain such as smoking and
substance use, both of which occur more frequently in
this group than in the general population [29]. We
propose a model where patients with schizophrenia in-
crease their intake of foods high in sugar and fat in order
to increase their low dopaminergic tone, which results
from dopamine receptor blockade, via endogenous opi-
oid release. The finding that medicated obese women
with schizophrenia have been shown to possess higher
circulating β-endorphin levels than matched controls
provides partial support for this hypothesis [30]. Medica-
tions with additional H1 receptor blockage impair satiety
signaling from GI tract to the hypothalamus; thus, there
is no “stop” signal for reward eating, which in turn
causes further weight gain.Clinical trials with the opioid receptor antagonist
naltrexone for obesity
Naltrexone is an oral agent that competitively antago-
nizes all known opioid receptors in the brain. Human
studies were completed in individuals with a range of ill-
nesses, including schizophrenia, and naltrexone has been
shown to be a safe and easy agent to use. It is shown to
decrease craving in alcoholics and is approved by the
The Food and Drug Administration (FDA) for the treat-
ment of alcohol dependence [31]. Naltrexone is reported
to decrease craving for other substances of abuse, like
nicotine. Furthermore, it has been shown to prevent sec-
ondary weight gain due to cessation of cigarette smoking
at low (25 mg and 50 mg), but not higher doses [32].
Naltrexone has been tested in human feeding studies,
and has been shown to reduce both the quantity of food
eaten and the choice of palatable foods [19]. A study
that was conducted for antidepressant- and lithium-
induced weight gain in bipolar women reported weight
loss during naltrexone treatment; however, weight on
average returned to baseline after cessation of active
treatment. Patients reported decrease in food cravings
while they received naltrexone, but not while taking
placebo in this study [33]. There is also a well-studied
bupropion/naltrexone combination for obesity treatment
[34,35]. Among several bupropion studies for smoking
cessation in schizophrenia concomitant to antipsychotic
use, only one –from our center- reported weight effects.
In this study, both bupropion and placebo groups gained
similar levels of weight regardless of their quit status
[36].Rationale and significance
In summary, obesity interventions in populations with
SMI are urgently needed. Current available medications
for this purpose are limited and have not been effective
in this population. Antipsychotic medication actions on
H1 and 5HT2 receptors only partly explain why they
cause weight gain. We developed a working hypothesis
that D2 receptor blockade might be partly responsible
for weight gain by interacting with the dopamine-opioid
system. Thus, we propose a randomized, double blind,
placebo controlled study of two different doses of nal-
trexone (25 mg & 50 mg) for adequate duration to coun-
teract antipsychotic induced weight gain.
Aims
To determine the efficacy of naltrexone versus placebo
for weight and health risk reduction in 144 obese indi-
viduals with SMI treated with an antipsychotic
medication.
Hypothesis 1
Subjects receiving naltrexone 25 mg and 50 mg for 52
weeks will lose weight, and improve BMI and waist
circumference, at a greater level than the subjects who
receive placebo.
Hypothesis 2
Both naltrexone arms will improve health risk markers
such as serum lipid profile, fasting glucose, and
glycosylated hemoglobin (HbA1c), better than placebo.
Exploratory aim
To determine the optimum effective dose of naltrexone
to counteract antipsychotic induced weight gain.
Methods
Study setting
The study will be run at the Connecticut Mental Health
Center (CMHC) and its affiliated satellite clinics
throughout the greater New Haven area. The expected
duration of the study is 5 years. The study has been
approved by The Yale University School of Medicine
Human Investigation Committee (HIC#1207010507),
and registered at ClinicalTrials.gov (NCT01866098). The
study will be conducted in accordance with the Declar-
ation of Helsinki and the International Conference on
Harmonization (ICH) - Good Clinical Practice (GCP)
guidelines for clinical trials.
Study population
One hundred and forty four patients with SMI will be
recruited from the CMHC and its affiliated satellite
clinics throughout the greater New Haven area. All
participants will be carefully assessed by physical
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lem that needs immediate attention will be referred to
each participant’s own primary care physician. All poten-
tial subjects will meet with study staff for intake and
evaluation sessions to determine eligibility prior to en-
rollment. Eligibility will be determined through partici-
pant report, chart review, and communication with their
CMHC clinician/psychiatrist, and this will be completed
by the Principal Investigator (PI) and research
coordinator.
Recruitment process
Subjects will be recruited through on-site flyers and clin-
ician referrals. The study will also be announced to all
the psychiatrists who are attending physicians at the
sites, as well as the administrative heads of each clinic
through team meetings and email lists. Subjects will be
prescreened for eligibility.
Retention strategy
Based on our experience with this population, and the
existing literature, we will implement strategies to
minimize attrition. These strategies are: 1) Provider rela-
tionship: The clinicians who work in the treatment sites
will be thoroughly informed about the study method-
ology, as well as the study's risks and benefits. The bulk
of recruitment will be from the CMHC, where the PI
has administrative responsibilities, and has direct access
to clinicians, as well as patients. 2) Information: During
the consent process, patients will be informed in detail
about the risks, benefits, duration, and requirements of
the study, as well as the importance of completing
follow-ups. Subjects will also be fully informed about the
possibility of being assigned to the placebo control
group. 3) Flexible scheduling: Assessment appointments
will be made around subjects’ schedules, including be-
fore or after hours, or right before/after clinical appoint-
ments at the same site. Calibrated portable scales will be
used for off-site appointments. 4) Transportation: If
transportation is not available, bus tokens, bus passes,
and city transportation for disabled subjects, when ne-
cessary, will be provided. Regular shuttles between sites
will be accessible to subjects for appointments. 5)
Missed appointments: Participants will receive early re-
minders both through study staff and from their clini-
cians. We will discuss missed appointments with the
participants, provide alternatives, and express our appre-
ciation of their efforts at every step. 6) Monetary
reinforcement: We are going to utilize an incrementally
increasing monetary compensation as the participant
moves through the study. Every milestone assessment
payment will be more than the previous one. Immediate
cash payments will be disbursed instead of checks. 7)
Lost to follow-up: In case of difficulty contactingsubjects, we will utilize clinicians’ help and schedule
clinical appointment times based on prior permission
from subjects during consent. Assessments in these
cases can be done right before or after the clinical ap-
pointment instead of scheduling future appointments. If
time or other considerations prevent the subject from
completing the entire assessment, we will prioritize
obtaining subjects’ weight, which is the primary outcome
measure, and they will still be partially compensated. 8)
Further participant refusal for assessments: After inquir-
ing about the reasons for discontinuing participation in
the study, if we cannot solve the immediate problem, we
will consider the refusal temporary and situational, and
ask for permission to re-contact at a later date. If the pa-
tient refuses re-contact, however, we will consider them
to have withdrawn from the study. 9) Monitoring Reten-
tion: We will implement review of each patient’s partici-
pation and risk for loss to follow-up at each team




1). Ages 18 to 75 years old
2).Meet DSM-IV criteria for schizophrenia,
schizoaffective disorder, bipolar disorder, major
depression, or another psychotic disorder based on
SCID interview
3). BMI of 28 or over
4).On a stable dose of antipsychotic medication; i.e. at
least one month with no dose change, and three
months from an antipsychotic switch
5). Deemed to be symptomatically stable by the clinical
staff for the past two months
6).Over 7% total body weight increased on
antipsychotics for the subjects within first year of
illness
Exclusion criteria
1).Meet criteria for current opiate abuse or dependence
(confirmed by positive urine drug screen for opiates
or, if suspected by study doctor via patient history
and or suspicion of occult opiate use, a naloxone
challenge will be performed.)
2). Current history of dementia or mental retardation
3).Not capable of giving informed consent for
participation in the study
4).Women who are pregnant or breast-feeding
5). Physical conditions affecting body weight (e.g.
Cushing’s disease, polycystic ovary syndrome)
6). Diabetes Mellitus (defined as prescribed an
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physician at screening)
7). Severe liver dysfunction (serum aminotransferases
greater than three times normal), acute infectious
hepatitis, liver failure.Study design
After screening for eligibility and signing the informed
consent, eligible subjects will be randomized to active
Naltrexone 25 mg, Naltrexone 50 mg, or placebo groups
in a 1:1:1 ratio using a computer randomization proced-
ure at the CMHC research pharmacy, blind to both
research team and subjects. Separate randomization
schedules will be applied based on gender and anti-
psychotic agent to yield an equal number of male and fe-
male subjects in each arm. This is to control for possible
differential gender effects of Naltrexone on weight as
well as differences brought on by higher and lower
weight liability medications.
Subjects will take the study medication daily for 52
weeks. Compliance will be monitored by pill counts as
well as 25 mg riboflavin added to the capsules which pro-
vides florescence to urine under Wood’s lamp (UV or
black light) [37,38]. Subjects will be given a study identifi-
cation card listing the fact that they may be taking nal-
trexone and this card will include the study emergency
cell phone number which will be available 24 hours a
day, 7 days per week in case of an emergency. Subjects
will be seen weekly for the first 4 weeks of the study;
thereafter they will be seen on a bi-weekly (every other
week) basis to be assessed (i.e. weight, side effect check,
paper questionnaires) throughout the remaining 48
weeks of treatment (Table 1).ble 1 Study flow
INI, PANSS, Demographics, Physical Exam
ine toxicology, pregnancy test for female subjects, fluorescence check in u
r compliance
sting Glucose, Insulin, HbA1c, Lipid Profile, Liver function tests, FTND
rum leptin, ghrelin, peptite YY, adiponectin, high sensitivity CRP, TNF-α, IL-
6, IL-18
amingham Score
tals (Blood Pressure, pulse)
eight, BMI
aist Circumference, 24hr Food Recall, BPRS, BDI, CDSS, C-SSRS, QCSRF, QLS-
-36, RMR, TFEQ, YPAS
U side effects
gnitive Battery (BACS)
breviations: BACS The Brief Assessment of Cognition in Schizophrenia, BDI Beck D
SS Calgary Depression Scale for Schizophrenia, C-SSRS Calgary Depression Scale f
e Mini-International Neuropsychiatric Interview, PANSS Positive and Negative Syn
S-Q-18 Quality of Life Enjoyment and Satisfaction Questionnaire, RMR: Resting Me
ree Factor Eating Questionnaire, YPAS The Yale Physical Activity Survey.Clinical and biochemical assessments
1). Intake interview including demographics, clinical
history, and The Mini-International
Neuropsychiatric Interview to ascertain diagnosis.
2). Urine toxicology (Utox) screen to rule out substance
use and pregnancy tests for female subjects.
3).Weight (Wt) to the nearest 0.1kg and height (ht)
will be measured to calculate BMI. Waist
circumference (wc) will be measured with a tape
measure placed on the midpoint between iliac crest
and lowest rib rounded to the nearest 5 mm. Our
lab has established procedures for wc measurement
(Interrater ICC = 95%). Resting blood pressure (bp)
and pulse will be measured.
4). Laboratory testing: All blood sampling is done via an
indwelling 21 gauge Intracath catheter placed in an
arm or hand vein. Fasting blood samples are
obtained from free-flowing blood, taking care to
discard fluid from the dead space of the system prior
to sampling and to leave the dead space filled with
heparinized saline (50 units/ml) after sampling.
Blood will be drawn by an institutionally






tabolica. Fasting glucose and insulin: Plasma glucose will
be analyzed by the glucose oxidase method
(Yellow Springs Instruments, Ohio). Plasma
immunoreactive insulin concentrations will be
determined with a double antibody
radioimmunoassay (Diagnostic, Webster, TX).
b. Lipid Profile: Total cholesterol (Total-C),
High-density lipoprotein (HDL-C), and
triglycerides (TG). Blood will be collected into
vacutainers containing no additive. SerumWeek 0
Week 0 and every 4 weeks subsequently + as needed
determined by study physician
Week 0, 16, 32, 52
Week 0, 16, 52
Calculated same time with blood draws.
Weekly for first 4 weeks, then every two weeks
Weekly for first 4 weeks, then every two weeks
Week 0 and every 4 weeks
Weekly for first 4 weeks, then every two weeks
Week 0, Week 16, Week 52
ion Inventory, BMI Body Mass Index, BPRS Brief Psychiatric Rating Scale,
izophrenia, FTND The Fagerström Test for Nicotine Dependence, MINI
Scale, QCSRF The Questionnaire on Craving for Sweet or Rich Foods,
Rate, SF-36 SF-36 Health Related Quality of Life Questionnaire, TFEQ
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determined by standard enzymatic procedures
(Sigma, St. Louis, MO).
c. Blood will be collected into vacutainers
containing EDTA. Assays of HbA1c will be
performed using an Ames DCA 2000 analyzer
(Miles, Inc., Elkhart, IN).
d. Serum leptin, ghrelin, peptite YY, adiponectin,
high sensitivity C-reactive protein (CRP),
interleukin 6, interleukin-1B, interleukin-18,
tumor necrosis factor alpha levels (TNF-α) will
be assayed by Yale Center for Clinical
Investigation core laboratories.
5). Brief Psychiatric Rating Scale (BPRS): This is one of
the most frequently used overall measure of
schizophrenia symptoms. It will be utilized to
demonstrate that the naltrexone does not cause any
worsening of the illness symptoms apart from the
usual fluctuations of the natural course [39].
6). Positive and Negative Syndrome Scale (PANSS):
This is a widely used scale to assess the severity of
positive and negative symptoms observed in
psychosis [40].
7). Beck Depression Inventory (BDI): 21-item version is
a widely used measure of the features and symptoms
of depression. The BDI taps a broad range of
negative affect – not just depression – and is a
highly efficient measure for detecting fluctuations in
broad psychopathology and distress [41].
8). Three Factor Eating Questionnaire, also known as
the Eating Inventory (TFEQ) is a measure of eating
behaviors with three factors: dietary (cognitive)
restraint, disinhibition, and hunger [42]. The TFEQ
is a frequently used measure in obesity trials. The
TFEQ has clinical utility to assess changes during
treatment as well as treatment outcomes [43]. A
24hr food recall is administered subsequent to
TFEQ in our lab protocol.
9). The Questionnaire on Craving for Sweet or Rich
Foods (QCSRF): The QCSRF is a two factor, nine-
item scale assessing the presence of cravings for rich
and sweet foods and has been found to have good
psychometric properties [44].
10). The Yale Physical Activity Survey (YPAS): is an
interview-administered questionnaire that assesses
activity participation in number of hours/week in
different categories (i.e. work, recreation, exercise)
and takes about 20 minutes to complete [45,46].
11). Resting Metabolic Rate (RMR): In our experience,
this group of subjects does not tolerate indirect
calorimetry measurements well even with portable
devices. Instead, we will utilize the Mifflin-St. Jeor
predictive formula, which is shown to be highly
predictive of indirect calorimeter measured RMR,and is best among the available formulas for this
specific population [47].
12). Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q-18): The Q-LES-Q-18 is
specifically designed to use with schizophrenia
patients and focuses on patient’s subjective
perception of various aspects of their life [48].
13). SF-36 Health Related Quality of Life Questionnaire
(SF-36): a 36-item short-form was constructed to
survey health status in the Medical Outcomes Study
[49]. The SF-36 was designed for use in clinical
practice and research, health policy evaluations, and
general population surveys. This instrument is
validated for use in patients with schizophrenia [50].
14). UKU Side Effect Checklist (UKU): This is a
comprehensive rating scale developed for
psychotropic drugs and a cross-sectional study of
side effects in neuroleptic-treated patients [51].
Common adverse events related to naltrexone will
be added to this scale, as needed.
15). Columbia-Suicide Severity Rating Scale (C-SSRS):
This is a scale developed for use in clinical trials of
psychoactive agents for the FDA to be used for
safety tracking of medications for suicidality [52].
16). Calgary Depression Scale for Schizophrenia
(CDSS): This scale is specifically designed for the
assessment of depression in schizophrenia and has
been used widely [53].
17). The Fagerström Test for Nicotine Dependence
(FTND): This is a scale used to assess nicotine
dependence [54].
18). Cognitive Battery. The Brief Assessment of
Cognition in Schizophrenia (BACS): Given the
cognitive impairment of schizophrenia, careful
assessment of cognition is necessary for determining
the feasibility of using any medication in this
population. This is a widely used cognitive battery
developed to assess cognition repeatedly in patients
with schizophrenia. It was found to be as reliable,
sensitive as a standard battery of tests that requires
longer time to administer [55,56].
Statistical analysis
Sample size and power calculation
The aim of this study is to compare the efficacy of two
different doses of naltrexone to placebo. In our pilot
study, an effect size of 1.53 (Cohen’s D) was achieved.
The power analysis assumes a similar weight loss differ-
ence between naltrexone and the placebo groups, a
two-tailed 0.05 significance level, 0.80 power, and the
worst case scenario of male subjects not responding to
naltrexone at all. A three group power analysis with a
significance level of 0.05 (two sided) was conducted
using GPower 3.03 software [57] after Cohen’s D was
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justed for post hoc analyses to detect a 1.52 kg difference
(1⁄2 SD of naltrexone group in pilot study) between nal-
trexone 25 mg and 50 mg doses, as well as between the
two genders. We will follow our protocol for retaining
subjects in the study very closely in order to reduce attri-
tion. However, since this is an unusually long study for
this cohort, we will inflate our sample size to adjust for
32% attrition, which was the intervention dropout rate in
our similar studies over one year. Thus the total sample
size will be 144, with 48 subjects in each arm, which
achieves a power of 0.81 if the pilot results hold.
Data analysis
Data will be double entered into databases and concord-
ance will be double-checked. Hard copy documents will
be examined to verify questionable observations. Missing
data will be examined for each variable. Histograms,
normal probability plots, and numerical summaries
(skewness, kurtosis) will be used to examine distribu-
tional assumptions required for the mixed model ana-
lysis described below.
Transformations such as the logarithm, square root,
and reciprocal will be considered in the event the nor-
mality assumption is inadequate. Residual analysis will
also be performed to evaluate distributional variance and
linearity assumptions. For all analyses, an alpha thresh-
old of 5% (two-sided) will be used to test for statistical
significance and will be performed using SAS v9.3 (SAS
Institute, Cary, NC).
Analyses will be performed according to the intent-to-
treat (ITT) principle where data from any randomized
subjects will be analyzed. We will calculate descriptive
statistics for participants at baseline, and compare naltrex-
one to placebo participants using analysis of variance
(ANOVA) for normally distributed covariates and chi-
square tests for categorical covariates. The impact of
baseline variables that demonstrate clinically relevant
group differences will be assessed in supportive analyses
using covariate adjustment.
Approach to missing data
The primary analysis method will use a likelihood-based
mixed model, which accommodates incomplete observa-
tions and operates under the assumption that the miss-
ing data is missing at random (MAR). Missing data
patterns, time to withdrawal and reasons for dropout
will be compared between two naltrexone and placebo
groups. T-tests, cross-tabulations, and logistic regression
will be used to evaluate whether withdrawal is
dependent on any observed variables. Finally, should
missing data patterns and reasons for missing data sug-
gest a bias or confounding, we will conduct sensitivity
analyses using pattern mixture models to examine theinfluence that dropout bias (informative missingness)
may have on treatment differences. Multiple imputation
(MI) will also be used in the case of data not MAR. Sen-
sitivity analyses will be performed secondarily among
study completers.
Hypothesis testing
The primary goal of this study is to compare the weight
changes resulting from two different doses of naltrexone
compared to placebo. The primary ITT analysis will em-
ploy a linear mixed effects model (LMM) to determine
the effect of treatment status (between-subjects for: nal-
trexone 25 mg/50 mg vs. placebo) on the trajectory of
weight change over time (within-subjects for: study time
points). The interaction between treatment and time will
be modeled and interpreted using graphical displays and
post-hoc contrasts on least square means. The latter will
include estimation of group contrasts at each time point
and polynomial (linear, etc.) contrasts for time within
each group. However, the primary contrasts will be each
dose compared with control at 52 weeks. Because the
outcome data are correlated (i.e., weight assessed from
the same subject at different time points), weight over
time will be modeled through the inclusion of random
subject effects and/or structured variance-covariance
matrices, with the best-fitting structure determined by
Bayesian-Schwartz Information criteria (BIC). Supportive
analyses will also include covariate adjustment for clinic-
ally significant variables (as determined from baseline
evaluations and also other treatment variables, such as
sessions attended). The above model will be fit using
SAS PROC MIXED (Cary, NC), using restricted max-
imum likelihood (REML). The proportion of subjects
achieving 5% weight loss will be compared between the
treatment groups with the Fisher’s Exact test. The effect
of treatment assignment on the secondary outcomes,
such as BMI, waist circumference, serum lipid profile,
fasting glucose, and HbA1c will be evaluated using the
linear mixed modeling approach described above. Type
1 error for secondary outcomes will be adjusted using
the Bonferroni correction, basing the adjustment on the
number of conceptually related statistical tests.
Other outcomes
Schizophrenia symptoms (BPRS), depression (BDI,
CDSS), dietary consumption (TFEQ), exercise (YPAS),
quality of life (Q-LES-Q and SF-36), cognition (BACS)
and metabolism/inflammation markers will be obtained.
Summary statistics (frequencies, percentages, means and
standard deviations, and medians and interquartile
ranges) will be calculated for naltrexone vs. placebo at
each time point. Appropriate parametric (for normally
distributed data) and non-parametric (deviation from
normality in data distribution) approaches will be used
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each time point. Depending upon the distribution of
these outcomes, the effect of naltrexone vs. placebo on
change over time in each outcome will also be examined
with GLMM, making appropriate model selections for
either binary or continuous outcomes.
Using UKU Side Effect Checklist and C-SSRS, we will
list and summarize side effects and suicidal tendencies
reported in each treatment group. Medication changes
that could not be avoided during the study will be exam-
ined in three groups: no change, change from a higher
weight liability to a lower weight liability medication,
and vice versa. Weight liability rankings of antipsy-
chotics will be based on earlier reviews [10,58]. Distribu-
tions of all variables will be evaluated for normality.
Alternative statistical approaches such as transforma-
tions or non-parametric tests will be used, as required.
Discussion
We will be conducting a randomized double blind
placebo-controlled study to investigate the safety and
efficacy of naltrexone 25 mg/day and naltrexone 50 mg/
day for weight and health risk reduction in obese indi-
viduals with SMI treated with antipsychotics. To our
knowledge, this is the first study investigating the safety
and efficacy of naltrexone, a widely available and inex-
pensive generic oral opioid antagonist, for the treatment
of antipsychotic induced weight gain. With this study
protocol, we have considered several different important
methodological issues. Since FDA obesity intervention
guidelines necessitate longer duration studies, we
planned the follow-up period to be 52 weeks. The sam-
ple size is also calculated in order to reach adequate stat-
istical power. We expect to recruit 144 patients without
encountering any problem within the scheduled time
period of 5 years, since CMHC and its affiliated satellite
clinics provide service to a large population with SMI. A
meta-analysis has shown that one-third of subjects drop
out of the randomized antipsychotic drug trials [59].
Thus, we expect a similarly high dropout rate for the
current study. In order to minimize attrition, we have
developed several retention strategies, which are detailed
in methods section. Moreover, we will inflate our sample
size to adjust for 32% attrition. Therefore, we expect to
achieve a sample size providing enough power to deter-
mine the efficacy of naltrexone for weight reduction.
Lack of compliance in schizophrenia is common: studies
demonstrate that around 50% of patients with schizo-
phrenia do not fully comply with the treatment [60], and
this may lead to false interpretation of the results.
Therefore, compliance will be closely monitored by pill
count. Although pill count is one of the most common
methods to monitor treatment compliance, it lacks ob-
jectivity [61]. Therefore, we aim to monitor treatmentcompliance by also using riboflavin as a urinary tracer,
which is strongly florescent under UV light. Riboflavin
at a dosage of 25 mg will be added to the study capsules,
and urine will be visually inspected under Wood’s lamp
(UV or black light) 37].
Our pilot study demonstrated all patients in the nal-
trexone arm lost significant weight during the study
period; however, in comparison to placebo, it was statis-
tically significant only for patients without diabetes. We
cannot conclude the underlying biological mechanism of
this finding with our current knowledge, but for this
clinical trial, we decided to exclude diabetic patients,
based on the findings of our pilot study. The exclusion
of patients with diabetes mellitus constitutes a major
limitation, particularly making the outcome difficult to
generalize to whole population with SMI. However, it
should be kept in mind that nearly 80% of the patients
with SMI are non-diabetics [62].
Another strength of this study is the evaluation of the
effect of naltrexone on several other measurements:
schizophrenia symptoms, depression, dietary consump-
tion, quality of life, cognitive functioning, physical activ-
ity, metabolism/inflammation markers: serum leptin,
ghrelin, peptite YY, adinopectin, high sensitivity CRP,
interleukin 6, interleukin-1B, interleukin-18 and tumor
necrosis factor alpha. Hopefully, the assessment of dif-
ferent outcome measures may help us to understand the
complex, overlapping, and interrelated elements of suc-
cessful weight loss, and the underlying mechanisms of
naltrexone in antipsychotic induced weight gain in SMI.
Overall, we hope that the results of this study may lead
to a novel pharmacological option for management of
this major health problem that has until now been lack-
ing adequate treatment.
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